Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia Aug 3, 2015 05:00PM
Genzyme (SNY), Isis Pharma (ISIS) Update on KYNAMRO Phase 3; Analysis Supports Further Study Nov 18, 2014 03:52PM
Isis (ISIS), Genzyme (SNY) Receive FDA Approval for KYNAMRO NDA Jan 30, 2013 06:37AM
Stocks Crossing 50-Day SMA 12/14: (ISIS) (GOL) (SNE) Above; (QCOM) (ARIA) (PAY) Below Dec 14, 2012 03:40PM
Genzyme (SNY), Isis Pharma (ISIS) Receive Negative Opinion from CHMP Over KYNAMRO Dec 14, 2012 07:31AM


Oct 18, 2012 05:33PM FDA votes to Approve KYNAMRO for Homozygous Familial Hypercholesterolemia (SNY) (ISIS)
May 29, 2012 09:23AM Sanofi's (SNY) Genzyme, Isis Pharma (ISIS) Says FDA Accepts NDA for KYNAMRO
Mar 29, 2012 11:02AM Sanofi's (SNY) Genzyme, Isis (ISIS) Submit KYNAMRO NDA to FDA for HoFH Treatment
Dec 15, 2011 08:05AM Isis Pharma (ISIS) Reports Delay in KYNAMRO NDA Submission
Jul 28, 2011 07:19AM Genzyme Submits NDA for Mipomersen to EMA; Select Kynamro as Brand Name (SNY) (ISIS)
Apr 14, 2011 07:52AM Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Pipeline Progress Review – Long-Term, Early Stage Programs Are Encouraging
Feb 17, 2011 10:34AM Canaccord Genuity Morning Coffee on Sanofi-Aventis (SNY) and Genzyme (GENZ): An Extra $5 Will Help The Medicine Go Down